Xencor, Inc. (FRA:XE9)

Market Cap	726.68M -46.7%
Revenue (ttm)	127.96M +38.2%
Net Income	-111.50M
EPS	-1.51
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	10.60
Previous Close	10.60
Day's Range	10.60 - 10.60
52-Week Range	5.60 - 18.20
Beta	n/a
RSI	34.93
Earnings Date	Feb 25, 2026

About Xencor

Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibodies for the treatment of asthma and allergic diseases, autoimmune diseases, and cancer. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; and Sotrovimab that targets the SARS-CoV-2 virus. It develops XmAb8...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1997
• Employees: 250
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: XE9

Financial Performance

In 2024, Xencor's revenue was $110.49 million, a decrease of -36.72% compared to the previous year's $174.62 million. Losses were -$232.62 million, 74.7% more than in 2023.

Financial numbers in USD